Carlyn Tan
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carlyn Tan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:47 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05775094 · A Study of Romosozumab in Women With Multiple Myeloma and OsteoporosisMemorial Sloan Kettering Cancer Center · active not recruiting · Osteoporosis, Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:47 UTC. The ranking covers the 200 most relevant of 339 PubMed records, and a shared surname and initials can bring in a namesake. All 339 on PubMed
- GPRC5D-Targeted CAR T Cells for Myeloma.N Engl J Med · 2022385 citationsRCR 25.1
- 364 citationsRCR 18.5
- 244 citationsRCR 11.0
- Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.Nephrology (Carlton) · 2005177 citationsRCR 5.2
- 173 citationsRCR 11.5
- Asymptomatic reactivation of JC virus in patients treated with natalizumab.N Engl J Med · 2009172 citationsRCR 4.4
- Perioperative endovascular internal iliac artery occlusion balloon placement in management of placenta accreta.AJR Am J Roentgenol · 2007138 citationsRCR 6.4
- 135 citationsRCR 3.6
- First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.JAMA Oncol · 2019134 citationsRCR 3.9
- Relative contributions of sympathetic, cholinergic, and myogenic mechanisms to cerebral autoregulation.Stroke · 2014123 citationsRCR 5.5